-
Mashup Score: 0
Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Emerging CAR-T therapies for T-cell lymphoma - 2 year(s) ago
Emmanuel Bachy, MD, PhD, Lyon Sud Hospital Center, Lyon, France, outlines novel promising CAR-T therapies in development for the treatment…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Learn more about emerging CAR-T therapies for T-cell lymphoma with Emmanuel Bachy in our exclusive interview from #EHA2022: π₯: https://t.co/3aUxsAtxdI @EHA_Hematology #HemOnc #LymSM #ImmunoOnc #CARTcell #tcellrx
-
-
Mashup Score: 4Efficacy of OriCAR-017, a GPRC5D-directed CAR T-cell therapy, in patients with R/R MM: Findings from the POLARIS study - 2 year(s) ago
OriCAR-017 is a second-generation, autologous, GPRC5D-directed CAR T-cell therapy that improves the expansion and durability of CAR T-cells post-transfusion.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Does OriCAR-017, a GPRC5D CAR T-cell, have potential to be the future sequencing therapy in patients with R/R MMβ Find out more π #mmsm #EHA2022 #ASCO22 https://t.co/ygAHdjJ0pH
-
-
Mashup Score: 4
The study met its primary endpoint, elucidating the adverse events associated with golidocitinib in patients with R/R PTCL. Preliminary data has demonstrated a favorable safety profile, comparable with that of currently approved therapies. The majority of TEAEs were found to be reversable or clinically manageable with dose alterations. Golidocitinib also demonstrated promising antitumor activity…
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
π A summary of preliminary data from the JACKPOT8 study: a phase I/II study of golidocitinib, a selective JAK1 inhibitor, in R/R peripheral T-cell lymphoma, presented at #EHA2022 π https://t.co/bvDq2Ui5iI π #lymsm #lymphoma https://t.co/KbJf1mgS5r
-
-
Mashup Score: 2Ibrutinibβs role in CLL treatment and future outlooks - 2 year(s) ago
Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses novel…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We spoke with @tobyeyre82 at #EHA2022, who shared some interesting insights into the role of ibrutinib in CLL treatment and future outlooks. Watch here: πhttps://t.co/kMOjYXk66Hπ @EHA_Hematology #HemOnc #CLLsm #LeuSM
-
-
Mashup Score: 1Insights into the DREAMM-14 trial - 2 year(s) ago
Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly discusses the DREAMM-14 trial (NCT05064358), which is…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Malin Hultcrantz (@MSKCancerCenter) shares some insights into the DREAMM-14 trial. Watch her interview here: π₯: https://t.co/W3rjJ0aRqS #EHA2022 #HemOnc #MMsm #ImmunoOnc @EHA_Hematology
-
-
Mashup Score: 0
In this video, Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
π£ @NicholasShortMD of @MDAndersonNews talks on combination therapies and their role in the ALL treatment landscape: β‘οΈ https://t.co/rZnuEyimvm @EHA_Hematology #EHA2022 #LeuSM #ALLsm #HemOnc #ImmunoOnc
-
-
Mashup Score: 1
During the EHA 2022 Congress, the AML Hub spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, What is the clinical significance of secondary-AML-type mutations in de novo AML.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
π¬ During #EHA2022 Congress, the AML Hub spoke with Isolda Fernandez, @Fundaleu. We asked, What is the clinical significance of secondary-AML-type mutations in de novo #AML π https://t.co/3cwbuyoYBg π #leusm #leukemia #AMLsm @Isoldafernande1 https://t.co/iaPH0GZgVx
-
-
Mashup Score: 0Preventing ibrutinib flare in CLL - 2 year(s) ago
In this video, Paul Hampel, MD, Mayo Clinic, Rochester, MN, discusses ibrutinib flare in chronic lymphocytic leukemia (CLL) and methods…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At #EHA2022, @hampel_p spoke with us and shared some insights into ibrutinib flare in CLL and methods to prevent this. Watch here: π₯: https://t.co/m7f2VNosQ8 #CLLsm #LeuSM #HemOnc @EHA_Hematology
-
-
Mashup Score: 1Is peripheral neuropathy in patients with DLBCL more severe after pola-R-CHP vs R-CHOP treatment? - 2 year(s) ago
During the EHA 2022 Congress, the Lymphoma Hub spoke with Marek TrnΔnΓ½, Charles University, Prague, CZ. We asked, Is peripheral neuropathy in patients with diffuse large B-cell lymphoma (DLBCL) more severe after pola-R-CHP vs R-CHOP treatment?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
π During #EHA2022 Congress, the Lymphoma Hub spoke with @MarekTrnenyDr, @CharlesUniPRG. We asked, Is peripheral neuropathy in patients with #DLBCL more severe after pola-R-CHP vs R-CHOP treatment? π https://t.co/1LcXKQd6cs π #lymsm #lymphoma https://t.co/W8F1LZu2KU
-
Jianxiang Wang of the Peking Union Medical College gives an overview of the COMMODORE trial evaluating the safety and efficacy of gilteritinib in R/R FLT3-mutated AML. π£ Watch now: https://t.co/4I6jCzuox3 @EHA_Hematology #EHA2022 #HemOnc #LeuSM #AMLsm